HemoHIM herbal extract,
does it really help with Enhancement of immune function and defense against infection in healthy adults?
research showsHemoHIM is rated C because a 38-person trial in subhealthy volunteers reported signals in natural killer cell activity and selected cytokine and immune-cell markers. Overall increases in white blood cells and lymphocytes were not significant, however, and the significant natural killer result was concentrated in the male subgroup receiving 6 g/day. No large independent trial showing fewer colds or other infections in healthy adults was identified, and the evidence is concentrated in the developer, manufacturer, and finished branded product.
ads claimMarketing translates changes in natural killer cells and cytokines into claims that immunity rises and people catch fewer colds. Immune-marker changes and reductions in the frequency or severity of actual infections in healthy adults are different clinical outcomes, and individual regulatory recognition does not itself establish infection prevention.
Useful facts when choosing a product
- A leading Korean finished product uses the individually recognized extract based on Angelica, Cnidium, and Paeonia, is manufactured by Kolmar BNH, and is widely distributed by Atomy.
- A representative liquid product contains 20 mL per pouch and is taken twice daily for a total of 40 mL; the daily label amounts are 3.5 mg of chlorogenic acid, 11 mg of nodakenin, and 30 mg of paeoniflorin.
- The 2006 immune-marker trial used 6 or 12 g/day of extract and should not automatically be considered identical to the current finished liquid amount or products with additional ingredients.
- A 2025 eight-week safety trial found no clinically important abnormalities but cannot establish long-term safety. Acute hepatitis cases linked to products distributed in Hong Kong warrant attention to symptoms and product source.
What the research actually shows
A 2006 Korea Atomic Energy Research Institute report allocated 38 subhealthy volunteers with peripheral white blood cell counts below 5,000 per microliter to placebo, HemoHIM 6 g/day, or 12 g/day for four months. White blood cell and lymphocyte counts showed nonsignificant trends, natural killer activity was significant in men receiving 6 g/day and only trended in other groups, and stimulated T-cell activity and selected interleukin-2, interferon-gamma, and interleukin-6 results were positive or trending. Antioxidant markers were null. A 2025 randomized trial of 96 healthy adults primarily evaluated safety of 40 g/day for eight weeks and did not test reduction of infection. A 2024 Iranian trial was positive in 42 mechanically ventilated intensive-care patients but concerned a different population. Animal immunosuppression research was not treated as evidence of human infection outcomes.
Why this is classified as C (40)
A small placebo-controlled human trial and product-specific immune-marker signals prevent D or an unknown rating. The evidence does not show a consistent primary clinical effect in the full population, relies on subgroups and surrogate markers, is concentrated in manufacturer- and developer-linked finished-product research, and lacks trials of actual infection reduction in healthy adults. The proprietary-product and surrogate boundaries therefore support C with 42 points.
Counterpoint. A product-specific signal in immune-cell activity remains possible, but it cannot be expanded into prevention of infection or treatment of disease.
Rejudgment record. New verdict — Subgroup immune-marker signals in a 38-person product-specific trial, capped at C because actual infection reduction is absent and evidence is concentrated in the developer and manufacturer
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement in natural killer cells, cytokines, and other immune markers in healthy or subhealthy adults | C | A 38-person product-specific trial found positive findings in selected subgroups and stimulated markers, while overall white blood cell and lymphocyte counts were not significant. |
| Reduction in the incidence or severity of actual infections in healthy adults | ? | No adequate human efficacy trial directly tracking colds or other infections in healthy adults was identified. The trial in ventilated intensive-care patients concerns a different population. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Choi HJ et al. KAERI/CM-869/2005, 2006 | Double-blind placebo-controlled human research report | 38 | Korea Atomic Energy Research Institute development program | White blood cells, lymphocytes, natural killer activity, stimulated T and B cells and cytokines, and antioxidant markers | White blood cell and lymphocyte increases were not significant, while natural killer activity was significant in men receiving 6 g/day. Selected T-cell and cytokine markers were positive or trending, and antioxidant markers were null. | Key |
| Khamooshpour G et al. 2024 | Randomized controlled clinical trial | 23 | Isfahan University of Medical Sciences research; product linkage unclear | Incidence of ventilator-associated pneumonia | Ventilator-associated pneumonia incidence decreased, but this was a small trial in a different population of mechanically ventilated intensive-care patients. | Different population |
| Seo JW et al. 2025 | Randomized double-blind placebo-controlled safety trial | 90 | Finished-product study with Kolmar BNH researchers as coauthors | Vital signs, blood and urine tests, and adverse events | No clinically important safety abnormality was found with 40 g/day for eight weeks, but the trial did not evaluate immune efficacy or infection reduction. | Safety |
| Kim SK et al. 2019 | Cisplatin-induced immunosuppression mouse study | Supported by Kolmar BNH | Natural killer cells, phagocytes, splenocytes, and T-helper cytokines | Immune-marker recovery was reported, but an immunosuppressed animal model cannot establish infection defense in healthy adults. | Preclinical |
Receipt — 5 References
All 5 cited sources were verified for existence at the original page (as of 2026-07-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] HemoHIM herbal extract x immune function and infection defense — Evidence Grade C·40. 5 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/hemohim-healthy-adult-immunity-infection-defense/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.